Alimera Sciences, Inc. (ALIM) Investment Research Dashboard
About Alimera Sciences, Inc. (ALIM) stock analysis
Get live ALIM stock price $5.54, comprehensive Alimera Sciences, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time ALIM stock data and investment insights.
Loading chart data...
Alimera Sciences, Inc. (ALIM) Overview
Alimera Sciences, Inc. (ALIM) is a publicly traded company in the Healthcare sector , specifically within the Drug Manufacturers - Specialty & Generic industry . As of the latest trading session, ALIM trades at $5.54 with a market capitalization of 301.29M . Over the past 52 weeks, ALIM has traded between $2.61 and $5.65 , with the current price positioned at approximately 96% of this range . T...
Key Takeaways
- Operates in the Healthcare sector (Drug Manufacturers - Specialty & Generic)
- Market cap: 301.29M
- Current price: $5.54
- 52-week range: $2.61 - $5.65
- P/E ratio: 5.28
Investment Score
A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.
Score unavailable for this asset.
0-39
Defensive posture
40-54
Mixed / wait for confirmation
55-69
Constructive setup
70-100
Attractive zone
Total Score
Value
Cheapness vs fundamentals and cash generation
Quality
Durability of profitability and balance sheet
Momentum
Price trend strength and persistence
Company Overview
Alimera Sciences, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic treatments globally, including in the United States. Its primary offering, ILUVIEN, is an intravitreal implant used to manage diabetic macular ede...
Company Information
- CEO
- Richard S. Eiswirth Jr.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 154
Contact Information
- Website
- https://alimerasciences.com
- Address
- 6310 Town Square
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Valuation metrics suggest potential value opportunity (P/E: 5.3)
✓ Higher growth potential with elevated volatility (Beta: 1.25)
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Alimera Sciences, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Alimera Sciences, Inc.
- ⚠Investors should consider how Alimera Sciences, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
301.29M
P/E Ratio (TTM)
5.28
Beta
1.25
Data Sources & Methodology
Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.
Related Stocks
Compare ALIM with peer companies:
- Price
- $0.78+0.00% (1D)
- Market cap
- 7.25M
- Price
- $0.20+0.00% (1D)
- Market cap
- 2.33M
- Price
- $1.30+5.69% (1D)
- Market cap
- 4.13M
- Price
- $0.72+0.00% (1D)
- Market cap
- 23.59M
- Price
- $6.31-0.94% (1D)
- Market cap
- 173.66M
- Price
- $0.00+0.00% (1D)
- Market cap
- 15.08K
- Price
- $4.39+1.15% (1D)
- Market cap
- 164.67M
- Price
- $0.51+24,371.43% (1D)
- Market cap
- 906.91K
- Price
- $0.00+0.00% (1D)
- Market cap
- 138.32K
- Price
- $0.34+0.00% (1D)
- Market cap
- 4.52M
- Price
- $2.53-0.78% (1D)
- Market cap
- 325.55M
- Price
- $0.00+0.00% (1D)
- Market cap
- 169.49K
- Price
- $2.79-4.45% (1D)
- Market cap
- 1.63M
- Price
- $0.06-17.48% (1D)
- Market cap
- 39.16K
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.
Healthcare (1D)
78/100 ⭐⭐⭐⭐⭐
- Overall
- +0.7%
- NYSE
- +0.6%
- NASDAQ
- +0.7%
| Sector | 1D | 1W | 1M | P/E | Score |
|---|---|---|---|---|---|
| Financial Services | +2.2% | +3.1% | +4.3% | 19.3 | 98/100⭐⭐⭐⭐⭐ |
| Healthcare | +0.7% | +1.3% | +1.6% | 24.1 | 78/100⭐⭐⭐⭐⭐ |
| Communication Services | +1.4% | -0.7% | +2.9% | 22.2 | 74/100⭐⭐⭐⭐⭐ |
| Consumer Defensive | -0.2% | +1.8% | +0.7% | 29.7 | 64/100⭐⭐⭐⭐ |
| Basic Materials | +0.4% | +1.2% | -0.2% | 25.2 | 61/100⭐⭐⭐⭐ |
| Real Estate | -0.5% | +0.0% | -2.5% | 29.2 | 43/100⭐⭐⭐ |
| Energy | -2.1% | -3.7% | -4.1% | 19.1 | 39/100⭐⭐ |
| Utilities | -1.0% | +0.0% | -4.4% | 26.8 | 37/100⭐⭐ |
| Industrials | +0.6% | +0.4% | -9.9% | 30.1 | 23/100⭐ |
| Consumer Cyclical | +0.5% | -1.5% | -5.8% | 43.0 | 18/100⭐ |
| Technology | +0.6% | -1.6% | -7.2% | 40.7 | 15/100⭐ |
Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.